
Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.
Today’s first-line treatment response consists mostly of intramuscular adrenaline injections, which means the Swedish firm’s nasal candidate could be a potential challenger on the established allergy market. One firm operating there is Danish firm ALK with its rescue pen, Jext.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app